EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01026246
First received: December 3, 2009
Last updated: March 28, 2013
Last verified: May 2012
  Purpose

Malaria is caused by a germ that people get from the bites of some mosquitoes. It kills over 2 million people each year. Many of the drugs used to treat malaria do not work as well as they used to and researchers are exploring other vaccines to prevent malaria. The purpose of this study is to learn if the vaccine, called EBA-175 RII-NG, is safe and if it strengthens the body's defenses against malaria. Participants will include 60 healthy adults, ages 18-40, recruited from Accra, Ghana. Several dosages of the vaccine will be tested for safety. The lowest dosages of the vaccine will be tested before the next higher dose is tested. There will be two groups for each dose, one group will receive the vaccine and the other group will receive a placebo (salt water solution). Participants may be involved in study related procedures for up to 398 days.


Condition Intervention Phase
Plasmodium Falciparum Malaria
Drug: Placebo
Biological: EBA-175 RII-NG Malaria Vaccine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Number of subjects experiencing severe (Grade 3) solicited injection site reactions. [ Time Frame: Within 14 days following vaccination. ] [ Designated as safety issue: Yes ]
  • Number of subjects experiencing severe solicited systemic reactions (Grade 3). [ Time Frame: Within 14 days following vaccination. ] [ Designated as safety issue: Yes ]
  • Number of subjects experiencing severe (Grade 3) clinical laboratory values. [ Time Frame: Within 14 days following vaccination. ] [ Designated as safety issue: Yes ]
  • Number of subjects spontaneously reporting adverse events considered associated with the vaccination that are severe (Grade 3). [ Time Frame: Duration of study. ] [ Designated as safety issue: Yes ]
  • Serious adverse events considered associated with the vaccination. [ Time Frame: Duration of study. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of subjects experiencing a 4-fold increase in Anti-EBA-175 RII-NG antibody level (ELISA). [ Time Frame: Days 14, 28, 42, 180 and 194 relative to baseline. ] [ Designated as safety issue: No ]
  • Relative binding inhibition of recombinant EBA-175 RII-NG to human red blood cells in vitro in the presence of serum from immunized individuals. [ Time Frame: Days 0, 14, 28, 42, 180 and 194. ] [ Designated as safety issue: No ]
  • Anti-EBA-175 RII-NG antibody level by enzyme-linked immunosorbent assay (ELISA). [ Time Frame: Days 0, 14, 28, 42, 180 and 194. ] [ Designated as safety issue: No ]
  • Relative growth inhibition of Plasmodium falciparum in human red blood cells cultured in vitro in the presence of serum from immunized individuals. [ Time Frame: Days 0, 14, 28, 42, 180 and 194. ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: June 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant
18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
Drug: Placebo
The placebo used will be normal saline (0.9 percent NaCl).
Biological: EBA-175 RII-NG Malaria Vaccine
EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
Experimental: Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant
18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
Drug: Placebo
The placebo used will be normal saline (0.9 percent NaCl).
Biological: EBA-175 RII-NG Malaria Vaccine
EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
Experimental: Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant
18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
Drug: Placebo
The placebo used will be normal saline (0.9 percent NaCl).
Biological: EBA-175 RII-NG Malaria Vaccine
EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.

Detailed Description:

Malaria accounts for 500 million febrile illnesses and more than a million deaths annually. The disease burden is heaviest in economically developing countries where it is estimated that up to 5 percent of the gross domestic product of sub-Saharan countries is consumed by the direct and indirect health costs of malaria. Researchers propose to conduct a Phase I dosage-escalating study to assess the safety and immunogenicity of 3 different dosages of erythrocyte-binding antigen 175 kDA region II-nonglycosylated (EBA-175 RII-NG) recombinant Plasmodium falciparum (Pf) vaccine adjuvanted with Adju-Phos (aluminum phosphate adjuvant): 5, 20, and 80 micrograms (mcg), given in 3 doses at 0, 1, and 6 months by intramuscular (IM) injection to healthy young adults in a malaria endemic area (semi-immune adults). One dose of vaccine will be given at each time point. The primary objective is to assess the safety and reactogenicity (tolerability) of ascending dosages of EBA-175 RII-NG vaccine among healthy subjects given in 3 IM doses at 0, 1 and 6 months. The secondary objective is to evaluate the immunogenicity of the EBA-175 RII-NG vaccine by measuring anti-EBA-175 RII-NG antibodies using enzyme-linked immunosorbent assay (ELISA), inhibition of Plasmodium falciparum growth in vitro, and inhibition of binding of EBA-175 RII-NG to red blood cells (RBCs). Participants will include 60 malaria semi-immune healthy subjects between the ages of 18 and 40 years, males and females, recruited from Accra, Ghana. Subjects will be randomized to receive 3 doses of the vaccine or saline placebo by the intramuscular route in a 9:1 ratio at 0, 1 and 6 months. The safety and immunogenicity of ascending dosages of the vaccine will be assessed. Eighteen subjects will receive vaccine at each of the following dosage levels: 5, 20, and 80 mcg. Two subjects will receive placebo for each dosage level. Dosage escalation will proceed only after review of the 2-week safety data of the 2 initial doses of the prior dosage level.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy males and healthy non-pregnant and non breastfeeding females between the ages of 18 and 40 years.
  • Females of childbearing potential must agree to practice adequate contraception through out the study and for 3 months after the third vaccination (including abstinence; hormonal contraception; condoms with spermicidal agents); males with female partners of childbearing age must agree to use condoms or other birth control.
  • Good health as determined by screening medical history, physical examination (PE), and routine laboratory assessments.
  • Willingness to comply with protocol requirements.
  • Ability to provide informed consent before any protocol procedures are performed.
  • Availability for follow-up for 12 months after the first immunization dose.

Exclusion Criteria:

  • Regular use of medications other than vitamins and contraceptives.
  • Current or recent (within the last 4 weeks prior to vaccination) treatment with parenteral, inhaled, or oral corticosteroids (intranasal steroids are acceptable), or other immunosuppressive agents, or chemotherapy.
  • History of splenectomy.
  • Abnormal screening laboratory values. Any abnormal screening value for any screening test, will exclude the subject from the study. An exception to this rule is the glucose measurement. Random plasma glucose will be measured on all subjects during the screening visit. Values higher than 110 mg/dl will be confirmed by a repeat fasting glucose measurement.
  • History of or current medical, occupational, social or family problems as a result of alcohol or illicit drug use by the volunteer.
  • History of moderate to severe mental illness, as defined by symptoms interfering with social or occupational function or suicidal thoughts/attempts.
  • History of receiving blood or blood products (such as blood transfusion, platelet transfusion, immunoglobulins, hyperimmune serum) in the previous 6 months.
  • Vaccination with a live vaccine within the past 30 days or with a non-replicating, inactivated, or subunit vaccine within the last 14 days.
  • Known hypersensitivity to components of the vaccine [Erythrocyte-Binding Antigen 175 kDa Region II-Nonglycosylated (EBA-175 RII-NG), sucrose, or aluminum adjuvant].
  • History of acute or chronic medical conditions including, but not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic and autoimmune/inflammatory conditions, sickle cell disease.
  • History of anaphylaxis or severe hypersensitivity reaction.
  • Severe asthma, as defined by an emergency room visit or hospitalization within the last 12 months.
  • Pregnant or breastfeeding women, or women unwilling to use effective contraception during the study period.
  • Acute illness, including temperature > 37.8 degrees Celsius within one week prior to vaccination.
  • Positive serology for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg).
  • Concurrent participation in other investigational protocols or receipt of an investigational product within the previous 30 days.
  • Identification of any condition that, in the opinion of the investigator, would affect the ability of the subject to understand or comply with the study protocol or would jeopardize the safety or rights of a subject participating in the study.
  • History of malignancy, including hematologic and skin cancers, or known immunodeficiency syndrome.
  • Pre-medication with analgesic or antipyretic in the 6 hours prior to vaccination, or planned medication with analgesic or antipyretic in the 24 hours following vaccination. This criterion should not preclude subjects receiving such medication after vaccination if the need arises.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01026246

Locations
Ghana
Noguchi Memorial Institute for Medical Research - Immunology
Legon, Greater Accra, Ghana
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01026246     History of Changes
Other Study ID Numbers: 08-0009
Study First Received: December 3, 2009
Last Updated: March 28, 2013
Health Authority: Ghana: Institutional Review Board
United States: Food and Drug Administration
United States: Institutional Review Board
United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Ghana, malaria, vaccine, Plasmodium falciparum

Additional relevant MeSH terms:
Malaria
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Aluminum phosphate
Antacids
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014